Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial
暂无分享,去创建一个
R. Plummer | M. Clarke | D. McAuley | I. Chau | R. Wilson | R. Barnes | Anne L. Thomas | A. Agus | R. McMullan | V. Coyle | C. McDowell | M. Grayson | C. Forde | Annmarie Doran | R. Adams | R. Mcmullan | R. Wilson
[1] C. Flowers,et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Aapro,et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] L. Leibovici,et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. , 2013, The Cochrane database of systematic reviews.
[4] F. Gibson,et al. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151) , 2013, Archives of Disease in Childhood: Education & Practice Edition.
[5] M. Paesmans,et al. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients , 2013, Supportive Care in Cancer.
[6] D. Rennie,et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. , 2013, Annals of internal medicine.
[7] J. Hoch,et al. Eliciting patients’ preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment , 2012, Supportive Care in Cancer.
[8] B. Yeap,et al. Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. , 2011, Journal of Clinical Oncology.
[9] G. Bonsel,et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.
[10] G. Antes,et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials , 2011 .
[11] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.
[12] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.
[13] Holger Schulz,et al. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. , 2009, The Cochrane database of systematic reviews.
[14] P. Clark,et al. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study , 2003, British Journal of Cancer.
[15] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[16] M. Paesmans,et al. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] P. Roberson,et al. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] L. Elting,et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] L. Casimir,et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer , 2000, Cancer.
[20] M. Paesmans,et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer , 1995, Antimicrobial agents and chemotherapy.
[21] R. Benjamin,et al. Outpatient treatment of febrile episodes in low‐risk neutropenic patients with cancer , 1993, Cancer.
[22] L. Young,et al. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] W Satterlee,et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. , 1971, The New England journal of medicine.